A detailed history of ETF Managers Group, LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, ETF Managers Group, LLC holds 42,393 shares of DVAX stock, worth $535,423. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,393
Previous 31,809 33.27%
Holding current value
$535,423
Previous $338,000 22.78%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$9.44 - $11.88 $99,912 - $125,737
10,584 Added 33.27%
42,393 $415,000
Q4 2022

Mar 23, 2023

SELL
$10.27 - $13.29 $56,618 - $73,267
-5,513 Reduced 14.77%
31,809 $338,000
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $25,659 - $45,064
-2,584 Reduced 6.48%
37,322 $390,000
Q2 2022

Aug 15, 2022

BUY
$7.45 - $12.83 $14,996 - $25,826
2,013 Added 5.31%
39,906 $510,000
Q1 2022

May 13, 2022

BUY
$9.75 - $14.44 $15,921 - $23,580
1,633 Added 4.5%
37,893 $417,000
Q4 2021

Feb 14, 2022

SELL
$13.17 - $20.94 $74,002 - $117,661
-5,619 Reduced 13.42%
36,260 $516,000
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $74,012 - $160,226
8,080 Added 23.91%
41,879 $814,000
Q2 2021

Aug 16, 2021

SELL
$7.25 - $10.99 $6,510 - $9,869
-898 Reduced 2.59%
33,799 $334,000
Q1 2021

May 17, 2021

SELL
$4.57 - $11.18 $84,860 - $207,601
-18,569 Reduced 34.86%
34,697 $323,000
Q4 2020

Feb 16, 2021

SELL
$3.73 - $5.6 $30,235 - $45,393
-8,106 Reduced 13.21%
53,266 $261,000
Q3 2020

Nov 16, 2020

BUY
$4.32 - $11.7 $134,879 - $365,297
31,222 Added 103.56%
61,372 $270,000
Q2 2020

Aug 14, 2020

BUY
$2.94 - $9.1 $88,641 - $274,365
30,150 New
30,150 $256,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.6B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.